Thanks, Doc! So, some perspective again. The l

Thanks, Doc!

So, some perspective again. The last 10Q shows 9 months net loss of ~$4.5MM. If we're selling 3cc Excellagen syringes now at a $5,700 margin, it doesn't take a lot of those to make the overall picture look pretty good...

Again, I doubt there were syringes flying out the door during Q4 to hit the 10k, but I hope we see something material. If we sold 100 of them, that's over $500k margin and a peek at where we're headed. I guess we'll see soon.

Then we can start to look forward to the 10Q due in 5 weeks ; )



===============
Posted By: Paul Jackson
Re: docj #8040
Thanks doc!

BTW - not sure if the data is correct, but when I checked D&B Hoovers, Hema Diagnostic Systems annual revenue is showing up as $7.5 million

Another revenue item on 10K would be Excellagen Sales since commercialization did start before end of July.

During the 6/21/2019, Joe said this...copied and pasted here -

"Thanks, Tony, I appreciate that. And, I’d just to say, you know, it’s good that we’re in commercialization mode and last week, when you sent that check from our distribution partner, McKesson, it was nice to see. It’s always nice to see when checks start rolling in from commercialization efforts and real sales. So, great job to you and your team, and I appreciate everything"

And, during the 21st Annual Global Investment Conference, Joe mentioned that Excellagen costs $100 to make but gnbt gets reimbursed $5800 for the large 3cc syringe...

That’s a great revenue source and bottom line driver...once the sales ramps up...